Skeletal phenotype amelioration in mucopolysaccharidosis VI requires intervention at the earliest stages of postnatal developmentJCI INSIGHTIF6.12023-11-083OA
An anti-ACVR1 antibody exacerbates heterotopic ossification byfibro-adipogenic progenitors in fibrodysplasia ossificans progressiva miceJOURNAL OF CLINICAL INVESTIGATIONIF13.62022-06-1513OAAI
Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1JOURNAL OF CLINICAL INVESTIGATIONIF13.62022-06-1516OAAI
Defining phenotype reversibility in lysosomal disease: Leveraging a COIN model in mucopolysaccharidosis type VI (MPS VI)MOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loopELIFEIF02020-06-0953OA
Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'ELIFEIF02019-01-304OA
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicityELIFEIF02018-09-1859OAAI
Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressivaNATURE COMMUNICATIONSIF15.72018-02-02166OAAI